ALK5-IN-79,2725056-38-0

ALK5-IN-79 产品活性：ALK5-IN-79 (compound 57) 是一种具有抗癌活性的 ALK 抑制剂，通过阻断 TGF-β1/SMAD 信号通路。ALK5-IN-79 减弱细胞外基质 (ECM) 的产生和胶原蛋白的沉积。ALK5-IN-79 具有良好的药代动力学特性和体内耐受性。 产品来源： www.medchemexpress.cn/alk5-in-79.html 研究领域：Protein Tyrosine Kinase/RTK 作用靶点：Anaplastic lymphoma kinase (ALK) In Vitro: ALK5-IN-79 (1000 nM; 2 h) has strong-to oderate inhibitory activities against ALK5, SRC, LCK, BRAF (V600E), RET, PDGFRα, EGFR and KDR at 1000 nM (inhibitory rate >20%) . ALK5-IN-79 (0, 0.125, 0.25, 0.5, 1.0 and 2.0 μM; 1 h) inhibits the phosphorylation of smad 3, at a dose-dependent pattern. In Vivo: ALK5-IN-79 (300 mg/kg/day; ip; every day for 7 days) decreases the weight of the mice. ALK5-IN-79 is safe in vivo. ALK5-IN-79 (10 and 50 mg/kg/day; iv; every other day for 24 days) resultes in tumor growth inhibition (TGI) rates of 61.9% and 80.5% in the Syngeneic Model, ALK5-IN-79 (10 and 50 mg/kg/day; iv; every other day for 24 days) resultes in tumor growth inhibition (TGI) rates of 62.1% and 75.6% in the PANC-1 subcutaneous xenograft model. ALK5-IN-79 inhibites pancreatic cancer tumor growth in a metrology-dependent manner. 相关产品：Crizotinib | Lorlatinib | Ceritinib | Entrectinib | Alectinib | Brigatinib | Repotrectinib | NVP-TAE 684 | GSK1838705A | MS4078 | AZD-3463 | CEP-37440 | Zotizalkib | Ensartinib dihydrochloride | R-268712 | Iruplinalkib | ALK inhibitor 2 | ALK-IN-1 | ASP3026 | KRCA-0008 | UNC5293 | TL13-112 | CPD-1224 | MS4077 | ALK kinase inhibitor-1 | Belizatinib | DDO-2728